Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 10/20 | 0.62 |
| ▸ | CTSL | P07711 | 7/20 | 0.62 |
| ▸ | CTSK | P43235 | 5/20 | 0.62 |
| ▸ | MAPK14 | Q16539 | 6/20 | 0.42 |
| ▸ | MAPK11 | Q15759 | 5/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.38 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.38 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.38 |
| ▸ | MAP3K20 | Q9NYL2 | 1/20 | 0.38 |
| ▸ | MAP3K4 | Q9Y6R4 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5842764 | 0.92 | CTSS (0.71) | CTSSCTSLCTSKALDH1A1 | |
| SCHEMBL5842433 | 0.86 | CTSS (0.62) | CTSSCTSLCTSK | |
| SCHEMBL5843392 | 0.85 | CTSS (0.60) | CTSSCTSLCTSKMAPK14ALDH1A1 | |
| SCHEMBL5841950 | 0.83 | CTSS (0.86) | CTSSCTSLCTSK | |
| SCHEMBL5841944 | 0.83 | CTSS (0.86) | CTSSCTSLCTSK | |
| SCHEMBL5842773 | 0.83 | CTSS (0.47) | CTSSCTSLCTSKALDH1A1 | |
| SCHEMBL5844301 | 0.81 | CTSS (0.49) | CTSSCTSLCTSKMAPK14MAPK11 | |
| SCHEMBL5842546 | 0.80 | CTSL (0.67) | CTSSCTSLCTSK | |
| SCHEMBL5842009 | 0.80 | CTSS (0.57) | CTSSCTSLCTSKALDH1A1 | |
| SCHEMBL5843533 | 0.79 | CTSS (0.56) | CTSSCTSLCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7109243-B2 | Inhibitors of cathepsin S | IRM LLC (BM) | 2006-09-19 | — | — | US | claimed |
| US-7109243-B2 | Inhibitors of cathepsin S | IRM LLC (BM) | 2006-09-19 | — | — | US | disclosed |
| WO-2004084842-A2 | INHIBITORS OF CATHEPSIN S | IRM LLC (BM) | 2004-10-07 | — | — | WO | disclosed |
| US-20040198780-A1 | Inhibitors of cathepsin S | IRM LLC (BM) | 2004-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198780-A1 | Inhibitors of cathepsin S | CTSS, CTSK, CTSE | CTSS 1/4885CTSL 10/4885CTSK 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.